Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. increased its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 74.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,019,380 shares of the company's stock after buying an additional 861,150 shares during the period. Alyeska Investment Group L.P. owned about 3.32% of Health Catalyst worth $14,277,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the company. Quantbot Technologies LP purchased a new stake in Health Catalyst during the 4th quarter worth approximately $29,000. Aquatic Capital Management LLC acquired a new stake in Health Catalyst during the 4th quarter worth about $63,000. Stoneridge Investment Partners LLC purchased a new stake in Health Catalyst during the 4th quarter valued at about $77,000. Martin Worley Group acquired a new position in shares of Health Catalyst in the fourth quarter valued at about $78,000. Finally, OneAscent Financial Services LLC purchased a new position in shares of Health Catalyst in the fourth quarter worth about $97,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded up $0.21 during midday trading on Thursday, reaching $4.18. 1,029,542 shares of the company's stock traded hands, compared to its average volume of 606,357. The company has a fifty day simple moving average of $4.15 and a two-hundred day simple moving average of $6.00. Health Catalyst, Inc. has a 1 year low of $3.56 and a 1 year high of $9.24. The company has a market cap of $293.48 million, a P/E ratio of -3.10 and a beta of 1.56. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HCAT shares. Stifel Nicolaus increased their price target on shares of Health Catalyst from $5.00 to $5.50 and gave the stock a "hold" rating in a report on Thursday. Evercore ISI downgraded shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Piper Sandler cut their price target on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada reduced their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group lowered their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Insider Activity

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company's stock, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the sale, the insider now directly owns 85,819 shares in the company, valued at $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,588 shares of company stock worth $217,259 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.